This randomized, blinded
Introduction
The endothelins (ET) are three related 21-amino acid peptides that are potent modulators of vascular tone, inducing vasoconstriction and under some conditions, vasodilation, as well as smooth muscle proliferation. They act on cell surface receptors that have been classified in mammals as ETA and ETB. The role of ET-2 is less certain in the cerebral vasculature and most work of relevance to vasospasm and subarachnoid hemorrhage (SAH) has involved ET-1.
Increased synthesis of ET-1 by cerebrovascular endothelial and possibly other central nervous system cells has been postulated to contribute to smooth muscle contraction and vasospasm after SAH.1, 9, 29) It follows that antagonism of the action of ET-1 might diminish vasospasm.
In support of this, a number of studies have demonstrated efficacy of ET receptor antagonists against vasospasm in various animal models.1-3, 5, 10-16, 21, 22, 26, 28, 32, 34-36) A limitation of most of these antagonists was that they are peptides that would need to be administered intracisternally in order to prevent vasospasm. This study tested the effects of a potent ETA receptor antagonist that crosses the blood brain barrier and would be expected to be active against vasospasm when administered systemically.24) The endpoints utilized were the degree of vasospasm assessed by comparison of arterial diameters on angiograms taken at baseline and 7 days after cisternal blood injection and drug administration, the levels of ET-1 plus ET-2 in cerebrospinal A similar but slightly lower level was observed at day 7 in vehicle-treated animals. There were no differences in ET-1 levels in CSF between groups at any time (Fig. 5) . In the basilar artery 7 days after SAH, ET-1 levels were higher in both PD156707-and vehicle-treated animals than in normal dog basilar artery although this was not statistically significant port an association between increased ET-1 levels and the post-SAH state. The association, however, does not prove that ET-1 causes vasospasm since ET-1 is elevated in other conditions that are not associated with vasospasm.9, 17) Since ET-1 secretion is controlled mainly at the level of transcription, changes in ET-1 messenger ribonucleic acid (mRNA) might be expected to occur after SAH. Hino et al.,9) however, found no change in ET-1 mRNA 7 days after SAH in monkeys although there was an increase in ETB receptor in vasospastic artery and in ETA and ETB receptors in the cerebral cortex. These changes were postulated to be compensatory changes to increase cerebral blood flow after SAH. They were similar to changes reported in ET receptor binding after SAH in dogs.26) The data suggest that alterations in ET and ET receptors occur after SAH but that they may be secondary to other pathophysiological processes involved in SAH.
That ET-1 causes vasospasm is also suggested by at least 19 studies of ET antagonists for prevention of vasospasm after experimental SAH. 1-3, 5, 10-16, 21, 22, 26, 28, 32, 34-36) The results have been variable and depend on a variety of factors such as the route and dose of drug adminstration, the model used, and the endpoints utilized. In summary, however, the majority of reports demonstrate that peptide antagonists such as BQ-123 have no or only a mild14) effect on vasospasm when administered systemically but do if given intracisternally. The nonpeptide drug bosentan decreased vasospasm when administered systemically to rats,1) rabbits,26, 36) and dogs26, 28, 34) but not when given intracisternally to monkeys.10) These studies are limited by the lack of measurements of drug levels. Zuccarello et al.36) documented oral activity of PD1550808 and bosentan and showed that adequate drug levels were present in plasma to account for the effects.
How can the efficacy of ET antagonists and the evidence that ET-1 levels are increased after SAH be reconciled with data showing no changes in ET-1 levels after SAH and that most studies of antagonist drugs show that vasospasm is decreased but not completely prevented by these drugs. In fact, in the present study, only about 10% of established vasospasm was acutely reversible with direct intraarterial infusion of PD156707 which is much less than can be reversed with other agents such as papaverine.19, 26) Normal cerebrovascular tone is a balance between vasoconstricting substances (prostanoids, ET) and vasodilating substances (nitric oxide or a related nitroso compound). Since SAH impairs nitric oxidemediated relaxation of cerebral arteries, the remaining influence is ET-induced vasoconstriction, the blockade of which would then decrease vasospasm. Furthermore, decreased nitric oxide production increases ET-1 production. 
